Duchenne Muscular Dystrophy: BMN 351 Treatment Study

We are testing a new treatment called BMN 351 to see if it is safe and well-tolerated in people with Duchenne Muscular Dystrophy. The study will also look at how the drug is processed in the body.

What diseases are being studied?

Health conditions and diseases that the clinical trial is designed to study and treat.

Who can participate in the clinical trial?

These questions help us understand your situation so we can let the trial team know whether you might be a potential match. This is not a medical evaluation and is not part of the official screening, the study doctor will make the final decision..

What experimental substances are being tested?

Experimental substances that are being investigated in this clinical trial. These are not yet approved for general use.

Exon 51 Specific Phosphorothioate Oligonucleotide
Bmn 351

Where is the clinical trial being conducted?

Locations and medical facilities where this clinical trial is currently recruiting or conducting research. Select the locations where you would like to participate.

Loading map...
Centro Clinico Nemo
Centro Clinico NeMO of Milano
Bresso, Italy
Fondazione Policlinico Universitario Agostino Gemelli IRCCS
Department of Women's, Child and Public Health Sciences
La Massimina-Casal Lumbroso, Italy
San Raffaele Hospital
Neurology
Vimodrone, Italy

Sponsor: Biomarin Pharmaceutical Inc.
Last updated: Nov 26, 2025

Disclaimer: Parts of this content have been automatically extracted from the EU Clinical Trials registry. While we strive for accuracy, please always contact the trial site or sponsor directly for correct and official information before making any decisions about participation. View on EU Clinical Trials.